Why is Biomaxima SA ?
1
High Debt Company with a Debt to Equity ratio (avg) at times
- High Debt Company with a Debt to Equity ratio (avg) at times
2
High Debt company with Weak Long Term Fundamental Strength
3
The company has declared Negative results for the last 8 consecutive quarters
- PRE-TAX PROFIT(Q) At PLN -0.21 MM has Fallen at -281.58%
- NET PROFIT(Q) At PLN -0.3 MM has Fallen at -273.22%
- DEBT-EQUITY RATIO (HY) Highest at 31.73 %
4
With ROE of 1.49%, it has a fair valuation with a 1.14 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -9.92%, its profits have risen by 115% ; the PEG ratio of the company is 0.2
5
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -9.92% returns in the last 1 year, the stock has also underperformed Poland WIG in each of the last 3 annual periods
How much should you hold?
- Overall Portfolio exposure to Biomaxima SA should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Biomaxima SA for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Biomaxima SA
-9.92%
-1.03
32.19%
Poland WIG
27.62%
1.38
19.95%
Quality key factors
Factor
Value
Sales Growth (5y)
4.88%
EBIT Growth (5y)
-40.97%
EBIT to Interest (avg)
11.03
Debt to EBITDA (avg)
2.19
Net Debt to Equity (avg)
0.28
Sales to Capital Employed (avg)
0.85
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
26.53%
ROE (avg)
24.44%
Valuation Key Factors 
Factor
Value
P/E Ratio
54
Industry P/E
Price to Book Value
1.14
EV to EBIT
68.60
EV to EBITDA
15.85
EV to Capital Employed
1.11
EV to Sales
1.20
PEG Ratio
0.21
Dividend Yield
NA
ROCE (Latest)
1.25%
ROE (Latest)
1.49%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Technical Movement
2What is working for the Company
INVENTORY TURNOVER RATIO(HY)
Highest at 4.18 times
-9What is not working for the Company
PRE-TAX PROFIT(Q)
At PLN -0.21 MM has Fallen at -281.58%
NET PROFIT(Q)
At PLN -0.3 MM has Fallen at -273.22%
DEBT-EQUITY RATIO
(HY)
Highest at 31.73 %
RAW MATERIAL COST(Y)
Grown by 1,360% (YoY
Here's what is working for Biomaxima SA
Inventory Turnover Ratio
Highest at 4.18 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Here's what is not working for Biomaxima SA
Pre-Tax Profit
At PLN -0.21 MM has Fallen at -281.58%
over average net sales of the previous four periods of PLN 0.12 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (PLN MM)
Net Profit
At PLN -0.3 MM has Fallen at -273.22%
over average net sales of the previous four periods of PLN 0.18 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (PLN MM)
Debt-Equity Ratio
Highest at 31.73 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 1,360% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales






